Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
Anne Peters, MD
Advertisement
Articles by Anne Peters, MD
Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5